Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (DART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04392505
Recruitment Status : Recruiting
First Posted : May 19, 2020
Last Update Posted : May 4, 2021
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Åslaug Helland, Oslo University Hospital

Brief Summary:

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation.

The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics.


Condition or disease Intervention/treatment Phase
Cancer Non Small Cell Lung Cancer Non Small Cell Lung Cancer Stage III NSCLC NSCLC, Stage III Drug: Durvalumab Injection Phase 2

Detailed Description:

This is an open, multinational, phase 2 trial to investigate the Properties of cancer cells before, during and after treatment with the investigational study drug durvalumab in patients with locally advanced non-small celled lung cancer (NSCLC). Both patients with high and low PD-L1 expression are allowed to participate. Durvalumab (PD-L1 inhibitor) will be administered after a period with standardtreatment with chemotherapy and radiationtherapy (chemoradiotherapy) for around 7 weeks. After maximum 5 weeks break after chemoradiotherapy, durvalumab will be given in the same dose to all patients for up to 12 months. The follow-up include a safety follow-up for up to five years, followed by a survival follow-up for up to a total of ten years.

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation.

The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: open, exploratory, multinational, phase 2 trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC Patients - a Phase II Translational and Biomarker Study Investigating PDL1 Positive and Negative Patients
Actual Study Start Date : May 11, 2020
Estimated Primary Completion Date : May 1, 2022
Estimated Study Completion Date : May 1, 2032

Resource links provided by the National Library of Medicine

Drug Information available for: Durvalumab

Arm Intervention/treatment
Experimental: The whole study population
All patients will receive durvalumab for up to 1 months after standard treatment With chemoradiotherapy.
Drug: Durvalumab Injection
Included patients will receive durvalumab (fixed dose, 1500mg Q4W) until progressive disease and no clinical benefit, intolerable toxicity or patient's wish, for a maximum duration of 12 months. Treatment with durvalumab should start <5 weeks after last radiotherapy dosing.
Other Name: Imfinzi




Primary Outcome Measures :
  1. Impact of tumour mutational burden (TMB) measured in the tumour tissue and blood samples, on the hazard. [ Time Frame: Throughout study, up to 5 years ]
    Analyses of TMB in tumour tissue. Patients with high Tumour Mutational Burden, TMB (> 8.5 mutations per megabase) have a hazard ratio equal to or less than 0.55 as compared to patients with low TMB. Tumor tissue will be analysed in regard to TMB, and several different cut-offs will be evaluated.


Secondary Outcome Measures :
  1. Predict assosiation between Tumour Mutational Burden, TMB, measured in tumour tissue and blood samples and clinical response [ Time Frame: Through study, up to 5 years ]
    To investigate different levels of TMB in tumor tissue compared to blood samples, as predictors for development of clinical response

  2. Specific RNA profiles predict response to treatment [ Time Frame: Through study, up to 5 years ]
    transcriptome characterization (RNA-sequencing) on tumour material to investigate this

  3. Impact of Molecular profiles in urine on response to treatment [ Time Frame: Through study, up to 5 years ]
    To investigate urine for predictive biomarkers (ctDNA, miRNA)

  4. Analysis of pre-treatment and under-treatment samples may identify biomarkers for predicting which patients will benefit from treatment with durvalumab after chemoradiation [ Time Frame: Through study, up to 5 years ]
    Analyses of biomarkers in tumour tissue.

  5. The durvalumab treatment following chemoradiation will induce T cell responses against antigens expressed in each patient´s tumor. [ Time Frame: Through study, up to 5 years ]
    Immunological response assessment performed on tumour material from participants.

  6. A possible change in PD-L1 status will be explored [ Time Frame: Through study, up to 5 years ]
    Immunohistochemistry of PD-L1 assessed on tumour tissue.

  7. The durvalumab treatment following chemoradiation has acceptable safety and tolerability in NSCLC patients, as assessed by Patient Reported Outcome measurements. [ Time Frame: Through study, up to 5 years ]
    Patient reported outcome measurements by standardized Tools; EORTC-QLQ-C30 and LC13.


Other Outcome Measures:
  1. The gut microbiome influence the responses to chemoradiation followed by durvalumab [ Time Frame: Through study, up to 5 years ]
    Genetic analyses on feces samples, by use of feces "Cards".



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Locally-advanced, unresectable, stage III NSCLC (including PET-CT and MRI-brain in the diagnostic work-up).
  2. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  3. Diagnostic biopsy with PD-L1 <1% in 50 patients PD-L1 ≥1% in 50 patients
  4. Adequate core or excisional biopsy for tumor assessment
  5. Age > 18 years at time of study entry
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  7. Life expectancy of at least 12 weeks
  8. Body weight >30 kg
  9. Adequate normal organ and marrow function as defined below:

    - Haemoglobin ≥9.0 g/dL

    • Absolute neutrophil count (ANC) 1.5 x (> 1500 per mm3)
    • Platelet count ≥100 x 109/L (>75,000 per mm3)
    • Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN).
    • AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be ≤5x ULN
    • Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:

    Males:

    - Creatinine CL (mL/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg/dL)

    Females:

    - Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)

  10. Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
  11. Women of childbearing potential (WOCBP) should have a negative urine or serum pregnancy within 7 days prior to receiving the firs dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A woman is considered as WOCBP, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
  12. WOCBP should use an adequate method to avoid pregnancy
  13. males who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for a period of 90 days (duration of sperm turnover) / the time required for the investigational drug to undergo five half-lives
  14. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion Criteria:

  1. Non-small cell lung cancer disease suitable for curative surgery
  2. Significant cardiac, pulmonary or other medical illness that would limit activity or survival
  3. Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study during the last 2 weeks.
  4. Any concurrent chemotherapy, Investigational Product (IP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
  5. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  6. History of allogenic organ transplantation.
  7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stableon hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
    • Patients with celiac disease controlled by diet alone

i. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent j. History of another primary malignancy except for

  • Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence
  • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • Adequately treated carcinoma in situ without evidence of disease k. History of active primary immunodeficiency or medical condition requiring high doses (>30 mg prednisolone daily) of systemic steroids or other forms of immunosuppressive therapy l. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), and hepatitis C. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

    m. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

  • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
  • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
  • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.

    n. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.

    o. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

    p. Prior randomisation or treatment in a previous durvalumab clinical study regardless of treatment arm assignment.

    q. Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

    r. Patients with grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study physician.

    s. Patients with irreverible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consulation with the Study Physician.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04392505


Contacts
Layout table for location contacts
Contact: Åslaug Helland, Prof, MD +47 22934000 ahh@ous-hf.no
Contact: Vilde D. Haakensen, MD vdd@ous-hf.no

Locations
Layout table for location information
Estonia
North Estonia Medical Centre Recruiting
Tallinn, Estonia
Contact: Kersti Oselin, MD       kersi.oselin@regionaalhaigla.ee   
Finland
Oulu University Hospital Recruiting
Oulu, Finland
Contact: Jussi Koivunen, MD       jussi.koivunen@ppshp.fi   
Tampere University Hospital Recruiting
Tampere, Finland, 33520
Contact: Jarkko Ahvonen, PhD       jarkko.ahvonen@pshp.fi   
Turku University Hospital Recruiting
Turku, Finland
Contact: Maria Silvionemi, PhD       maria.silvionemi@tyks.fi   
Contact: Kirsi Penttilä       kirsi.penttila@tyks.fi   
Lithuania
National Cancer Institute Recruiting
Vilnius, Lithuania
Contact: Saulius Cicenas, MD       saulius.cicenas@nvi.lt   
Norway
Haukeland universitetssykehus Recruiting
Bergen, Norway
Contact: Marianne Aanerud, MD       marianne.aanerud@helse-bergen.no   
Oslo University Hospital Recruiting
Oslo, Norway
Contact: Åslaug Helland, MD, PhD, Prof         
Stavanger University Hospital Recruiting
Stavanger, Norway
Contact: Tesfaye Madebo         
Universitetssykehuset i Nord-Norge Recruiting
Tromsø, Norway
Contact: Nina Helbekkmo, MD       nina.helbekkmo@unn.no   
St. Olavs Hospital Recruiting
Trondheim, Norway
Contact: Bjørn Henning Grønberg, MD       bjorn.h.gronberg@gmail.com   
Sponsors and Collaborators
Oslo University Hospital
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Åslaug Helland, Prof, MD Oslo University Hospital
Layout table for additonal information
Responsible Party: Åslaug Helland, Prof, MD, Head of Research, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT04392505    
Other Study ID Numbers: DART
First Posted: May 19, 2020    Key Record Dates
Last Update Posted: May 4, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Durvalumab
Antineoplastic Agents, Immunological
Antineoplastic Agents